On this episode of Stock Movers:
- NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade.
- Sanofi’s profit rose more than analysts expected last quarter, lifted by demand for its blockbuster skin and asthma drug Dupixent. 
- Saab boosted its organic revenue forecast for the full year, benefiting from the uncertainty of the geopolitical landscape, adding it's received a record high order backlog.

On this episode of Stock Movers: - NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade. - Sanofi&rsquo;s profit rose more than analysts expected last quarter, lifted by demand for its blockbuster skin and asthma drug Dupixent. - Saab boosted its organic revenue forecast for the full year, benefiting from the uncertainty of the geopolitical landscape, adding it's received a record high order backlog.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

NatWest Rises, Sanofi Climbs, Saab Surges

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ad2997b9-1dcd-40ae-96f0-b38000862450/transcript

Advertisement